Sutro Biopharma is a clinical-stage biotechnology company developing site-specific and novel-format antibody-drug conjugates (ADCs) for the treatment of oncology. The company utilizes its proprietary integrated cell-free protein synthesis platform, XpressCF, and site-specific conjugation platform, XpressCF+, to design therapeutics including single-payload ADCs, bispecific ADCs, immunostimulatory ADCs, and dual-payload ADCs. Its lead wholly-owned product candidate, STRO-004, is a homogeneous ADC directed against tissue factor for the treatment of solid tumors, currently in Phase 1 clinical trials. Other pipeline assets include STRO-006, an ADC targeting integrin alpha v beta 6, and STRO-227, a dual-payload ADC targeting Protein Tyrosine Kinase 7. Sutro has established collaborations with pharmaceutical partners including Astellas Pharma, Merck, Bristol Myers Squibb, and EMD Serono for the development of various ADC programs. The company also supports vaccine discovery for Vaxcyte using its cell-free protein synthesis technology. Sutro focuses on creating optimized, homogeneous product candidates against clinically validated targets to address unmet medical needs in cancer care.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage sutrobio.com
Sector Healthcare IR page ir.sutrobio.com
Tags
antibody-drug conjugates, cell-free protein synthesis, oncology, solid tumors, dual-payload adcs, immunostimulatory adcs, site-specific conjugation, protein therapeutics, cancer therapy, XpressCF, XpressCF+, STRO-004, STRO-006, STRO-227, STRO-002, STRO-001, luveltamab tazevibulin, luvelta, Astellas Pharma, Merck Sharp & Dohme, Celgene, Bristol Myers Squibb, EMD Serono, Vaxcyte, Ipsen
Press page —

Metrics

Valuation  
Market cap $ 267.405M
Market cap (USD) $ 267.405M
P/E -0.58
PEG —
P/BV -2.02
P/S 5.93
P/OCF -2.07
P/FCF -1.49
Dividend yield —
Turnover / mcap —
Returns  
ROE 144.3%
ROI —
ROIC —
Profit margin -186.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -71.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 102.484M 62.043M 153.731M 67.772M 61.88M 42.722M 42.736M 38.419M 51.741M
Net profit -191.086M -227.461M -106.793M -119.204M -105.538M -32.128M -55.744M -35.317M -19.688M
Free cash flow -178.926M -194.638M -115.931M -4.309M -97.002M — — 11.126M -40.389M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 11.57 5 4.71 7.75 18.62 22.37 11.08 15 —
Price performance 12m 1.31 0.06 -0.39 -0.58 -0.17 1.02 -0.26 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 1.62M 2.49M 6.3M 5.56M 12.5M 7.12M 36.1M 8.62M 3.98M
↳ YoY growth +53.3% +153.0% -11.7% +124.0% -42.8% +406.6% -76.1% -53.8%
↳ 5y CAGR +34.4% +70.7% +6.5% -6.5%
Borrowings, current (USD) — 14.6M 4.72M 1M — 9.38M 12.5M 4.06M — —
Borrowings, non-current (USD) — — 10M 8.88M 24.5M 15.7M 3.77M 0.00 — —
Lease liabilities (USD) — — — — 30.7M 32.3M 34.2M 29.6M 23.2M 15.7M
Cash and deposits (USD) 11.6M 22M 125M 4.96M 206M 30.4M 47.3M 69.3M 190M 58.1M
Right-of-use assets (USD) — — — — 29.7M 29M 26.4M 22.8M 17.7M 10.9M
Net debt (borrowings + leases - cash) (USD) — -7.39M -111M 4.92M -182M 27M 3.18M -35.6M — —
Cash flow detail
Operating cash flow (USD) -13.2M -37.1M 12.7M -65M -67.8M -81.7M 3.55M -112M -192M -177M
Purchases of property, plant and equipment (USD) -4.39M -3.32M -1.56M — — — — — — —
Change in receivables (cash effect) (USD) -171,000 -1.05M -865,000 -3.81M 739,000 -6.9M 5.34M -29M 27.5M 4.64M
Change in payables (cash effect) (USD) 874,000 -473,000 209,000 2.25M -947,000 6.43M -1.23M 4.81M 706,000 -2.47M
Share buybacks (cash effect) (USD) — — — — — -7,000 — — — —
Interest paid (cash effect) (USD) 0.00 -479,000 -1.28M -1.05M -1.68M -2.05M -1.87M -1.13M -310,000 0.00
Income taxes paid (cash effect) (USD) — — — — — -103,000 0.00 -379,000 -17.5M -75,000
Share-based compensation (USD) 968,000 1.39M 2.87M 10.3M 11.9M 23.2M 26.3M 24.9M 24.7M 14M
Operating cash flow before change in receivables (USD) -13M -36M 13.5M -61.2M -68.5M -74.8M -1.79M -82.7M -219M -182M
Free cash flow (OCF - PPE - intangibles) (USD) -17.5M -40.4M 11.1M — — — — — — —
Income detail
Research and development expense (USD) 43.6M 54.6M 54.3M 65.6M 77M 104M 137M 180M 252M 166M
↳ 5y CAGR +19.1% +20.2% +27.2% +30.9% +16.7%
Total comprehensive income (USD) 1.74M -19.7M -35.4M -55.5M -32.2M -106M -120M -106M -227M -191M
Comprehensive income to owners (USD) 1.74M -19.7M -35.4M -55.5M -32.2M -106M -120M -106M -227M -191M
Reported Apr 1, 2019 Apr 1, 2019 Apr 1, 2019 Mar 16, 2020 Nov 10, 2021 Feb 28, 2022 Mar 13, 2025 Mar 25, 2024 Mar 13, 2025 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

– STRO-006, ITGB6-targeting ADC, enters clinic with first patient dosed; initial update expected second half of 2027 –

– STRO-227, Sutro’s PTK7-targeting dual-payload ADC, advancing toward clinical development early 2027 –

– Astellas dosed first patient in second dual-payload iADC program, triggering milestone payment to Sutro –

– Strong balance sheet with $142.2 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to support operations into first half of 2028 –

SOUTH SAN FRANCISCO, Calif., November 12, 2026 -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the third quarter ended September 30, 2026 and recent business highlights.

October 21, 2026 8:00am EDT Download as PDF

— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —

      — Initial clinical data expected in the second half of 2027 —

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of solid tumors. STRO-006 is the Company’s potential best-in-class integrin β6 (ITGB6)-targeting exatecan ADC with a drug-to-antibody ratio of 8 (DAR8), engineered for optimized pharmacokinetics, tolerability and a differentiated therapeutic index.

“Dosing the first patient with STRO-006 marks our second ADC to enter the clinic in less than a year and reflects the Sutro team’s exceptional execution of our pipeline strategy,” said Jane Chung, Chief Executive Officer of Sutro. “ITGB6 is difficult to target due to complex biology and is expressed across a broad range of tumors with high unmet need, including non-small cell lung and head and neck cancers. In preclinical models, STRO-006 demonstrated potent, sustained anti-tumor activity with minimal on-target toxicity, supporting our belief that Sutro’s advanced design capabilities can widen the therapeutic index and deliver a differentiated safety and efficacy profile. We look forward to advancing STRO-006 in the clinic and evaluating its potential to benefit patients.”

The Phase 1, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of STRO-006 in adults with advanced or metastatic solid tumors. The dose-escalation portion will enroll patients with ITGB6-expressing tumor types, including head and neck cancer, non-small cell lung cancer, esophageal/gastric cancer, colorectal cancer, endometrial cancer, urothelial cancer and breast cancer. The trial will evaluate STRO-006 across ascending dose levels beginning at 1.5 mg/kg. This starting dose is enabled by Sutro’s precise design capabilities and supported by the tolerability observed in non-human primates at doses up to 30 mg/kg.

More information can be found at:  https://clinicaltrials.gov/study/NCT07807345

About STRO-006

STRO-006 is Sutro’s next-generation DAR8 ADC targeting integrin β6 (ITGB6), a tumor-associated antigen expressed across several high-prevalence solid tumors. This candidate delivers a potent exatecan payload attached via a site-specific β-glucuronidase cleavable linker to a high-affinity antibody that binds to ITGB6 without disrupting TGFβ signaling. STRO-006 is designed to deliver a wider therapeutic index than conventional ADCs by enhancing selectivity, stability, and pharmacokinetics. In preclinical studies, STRO-006 demonstrated strong and durable anti-tumor activity. STRO-006 is currently being evaluated in a Phase 1 trial in patients with a range of ITGB6-expressing solid tumors.

About Sutro Biopharma

Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.

For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

The information contained in each post on this page was factually accurate on the date it was issued and posted. 

Search for:

17th Annual World ADC Conference – Presentations


Oct 14, 2026

Next-Generation High DAR TOPO1i x DDRi Dual-Payload ADCs to Improve Efficacy, Overcome Resistance & Enhance Safety Presenter: Krishna Bajjuri, Ph.D.Plenary Session: Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design...

read more

AACR Annual Meeting 2026 – Presentation and Posters


Apr 21, 2026

STRO-004, a Next-Generation Tissue Factor (TF)-Targeted DAR8-Exatecan ADC, Demonstrates Superior Efficacy Across TF-Expressing Solid Tumors in a Comprehensive Single-Mouse PDX Trial Presenter: Genevive Hernandez, Ph.D.Phase 1 open-label study to evaluate safety,...

read more

16th Annual World ADC London Summit – Presentation


Feb 27, 2026

Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms Presenter: Hans-Peter Gerber, Ph.D., Chief Scientific Officer

read more

Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting – Poster Presentation


Nov 19, 2025

Next-Generation Immunostimulatory Antibody-Drug Conjugates (iADCs) Combine Tumor Cell Killing with Immune Activation to Induce Durable Antitumor Immunity

read more

16th Annual World ADC San Diego – Presentations


Nov 19, 2025

Showcasing Development of Site-Specific, High-DAR Dual-Payload ADCs Presenter: Daniel Calarese, Ph.D.Developing Next-Generation Immunostimulatory Dual Payload ADCs to Enhance Therapeutic Index & Tackle Patient Resistance Presenter: Gang Yin, Ph.D.Laying Out...

read more

Sutro R&D Day – Presentation


Nov 12, 2025

read more

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025


Nov 5, 2025

SOUTH SAN FRANCISCO, Calif., November 5, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research &...

read more

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference


Nov 3, 2025

SOUTH SAN FRANCISCO, Calif., November 3, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC...

read more

Whitepaper: The Power of Partnership in Advancing Innovation


Oct 29, 2025

Sutro Biopharma and Boehringer Ingelheim collaborate to scale-up a novel cell-free technology platform to produce ADCs. Explore how cell-free ADC manufacturing is shaping cancer therapy. 

read more

21st Annual PEGS Boston Summit – Presentation


May 16, 2025

read more

« Older Entries

Dedicated to patients
and changing the future of oncology

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

GDPR Cookie Banner

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Accept

Close GDPR Cookie Settings

Sutro Biopharma, Inc.

  • Privacy Overview
  • Strictly Necessary Cookies

Powered by  GDPR Cookie Compliance (opens in a new tab)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enabled Disabled

Enable All Save Settings

Prompts

Sutro Biopharma, Inc. (ticker STRO), listed in United States.

ETFs Holding Sutro Biopharma, Inc.

ETF Weight in ETF Shares Market value As of
WCEO 0.18% 740 $ 17.886K Jul 31, 2026
VFMO 0.07% 69,761 $ 1.412M Aug 31, 2026
FSEG 0.06% 102 $ 3,386.40 Jun 30, 2026
RESM 0.02% 17 $ 564.40 Jun 30, 2026